Citius Oncology, Inc. (CTOR)

Market Cap	70.59M
Revenue (ttm)	n/a
Net Income (ttm)	-19.52M
Shares Out	71.30M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,409
Open	1.000
Previous Close	0.984
Day's Range	0.950 - 1.025
52-Week Range	0.925 - 49.000
Beta	n/a
Analysts	Strong Buy
Price Target	6.00 (+506.06%)
Earnings Date	Nov 29, 2024

About CTOR

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: CTOR

Financial Performance

Financial numbers in USD

Analyst Forecast

According to one analyst, the rating for CTOR stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(506.06% upside)

Analyst Consensus: Strong Buy